Loading...
Market
Story
Scholar Rock's Apitegromab Succeeds in Phase 3 SMA Study, Stock Surges Over 300% with p=0.019
Oct 7, 2024, 12:20 PM
Scholar Rock announced that its drug apitegromab met the primary endpoint in a Phase 3 SAPPHIRE study for treating spinal muscular atrophy (SMA). The study demonstrated a statistically significant and clinically meaningful improvement in motor function among patients, with a p-value of 0.019. The trial design included patients with SMA type2/3 who were already on existing treatments such as Spinraza and Evrysdi, despite lowered statistical power for individual arms. Following the positive trial results, Scholar Rock's stock surged over 300%. The successful outcome of this late-stage trial positions Scholar Rock as a significant player in the biotech industry, with expectations of further regulatory approvals.
View original story
Similar markets
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
Yes • 50%
No • 50%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
